@article {Brogsitter2112, author = {Claudia Brogsitter and J{\"o}rg Pinkert and Jan Bredow and Thomas Kittner and J{\"o}rg Kotzerke}, title = {Enhanced Tumor Uptake in Neuroendocrine Tumors After Intraarterial Application of 131I-MIBG }, volume = {46}, number = {12}, pages = {2112--2116}, year = {2005}, publisher = {Society of Nuclear Medicine}, abstract = {131I-labeled metaiodobenzylguanidine (MIBG) is an established treatment modality for neuroendocrine tumors. Because of low tumor doses, it has a predominantly palliative character. Our approach was to investigate whether intraarterial application of 131I-MIBG has the potential to enhance tumor uptake. Methods: Seventeen patients with primary or metastasized neuroendocrine tumors received intraarterial treatment with 131I-MIBG, and 12 of these patients also had intravenous treatment. Every patient underwent intravenous 131I-MIBG whole-body scanning before therapy. For quantification, a tumor{\textendash}to{\textendash}whole-body ratio was calculated from the diagnostic and 24-h posttreatment scans. Results: Compared with the intravenous application, intraarterial 131I-MIBG treatment provided an up to 4-fold higher tumor uptake. Mean uptake was enhanced by 69\%, but this varied widely between patients. We did not observe any immediate complications from catheterization. Carcinoid-related side effects were noted in 7 of 17 patients and were not different from those seen with intravenous application. Conclusion: Intraarterial treatment with 131I-MIBG is a safe alternative to intravenous application and provides a 69\% higher mean tumor uptake. We propose to attempt intraarterial MIBG treatment in every patient to assess its potential benefit.}, issn = {0161-5505}, URL = {https://jnm.snmjournals.org/content/46/12/2112}, eprint = {https://jnm.snmjournals.org/content/46/12/2112.full.pdf}, journal = {Journal of Nuclear Medicine} }